Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia

समान संसाधन

• Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
  द्वारा: Sallman, DA, और अन्य
  प्रकाशित: (2015)
• TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
  द्वारा: Sallman, David A., और अन्य
  प्रकाशित: (2020)
• Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
  द्वारा: Sallman, David A., और अन्य
  प्रकाशित: (2021)
• TP53 and IDH2 somatic mutations are associated with inferior overall survival following allogeneic hematopoietic cell transplantation for myelodysplastic syndrome
  द्वारा: Kharfan-Dabaja, Mohamed A., और अन्य
  प्रकाशित: (2017)
• Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes
  द्वारा: McGraw, Kathy L., और अन्य
  प्रकाशित: (2018)